Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
about
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionOutcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.Hepatitis C transmission and treatment in contact networks of people who inject drugs.Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.Current and emerging antiviral treatments for hepatitis C infectionCombination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsTreatment decisions and contemporary versus pending treatments for hepatitis C.Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984.The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.How "hidden" are unobserved networks among people who inject drugs?Influence of healthcare-associated factors on the efficacy of hepatitis C therapyHCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era
P2860
Q26801456-8928F5F9-F6AA-4534-BC36-7327B0CC78B4Q33821728-B06C1886-6FC0-421A-A684-F4A7D91D3C26Q35040866-F7ECDD71-1C6D-43A6-9A81-5BDFD47C8225Q35565944-F1C13EC3-FE72-44DD-B43E-CC13A543CFB4Q36009357-830C3F63-EE3C-4454-8961-6F30DB06FC5BQ36286654-7E2B5F01-0EC3-47BC-97CB-9C7AC8A2E52FQ36729900-03BD0922-C50D-4835-B2FC-6FAE23A38DC4Q37042425-48E5D528-2367-4169-8151-BAB0A1462FE3Q37455611-F1AA0B0B-5D44-4368-87F5-081693A4AD00Q37601315-3A316D94-1742-4188-8F5C-F237F6A7E902Q38135774-C6849CE5-816B-43CF-BF70-75DA1B1155CEQ38255693-0963A0AF-6487-4821-A4E1-591ADD61FBE3Q38407675-5D40026B-5BF8-43C4-A93D-EABEB55BE839Q38800572-21D14601-D309-43CD-84D1-84C55600568AQ39269740-BF00B0DB-4408-43E1-9B0E-DBD44FA3D1B4Q40364008-DEC56A55-5A86-45D7-BCBF-3FF8FBC8CE35Q40931707-FAF6B2FA-2E09-4D6E-9B12-494EA279614EQ41546485-44C3819E-E100-4320-94B2-2B5FEC33C969Q41703740-62420D38-6B0B-4927-B212-7ACF14E60FB9Q42197246-E40A9C8C-7861-4D6D-8A53-224926179B35Q45324462-D80E9CE9-8A2A-4FC6-9F9F-A8F9BD4D1944Q47603693-33F09C15-4349-4794-B9D3-0AF61AB8DCE0Q55303632-FBD40B23-A702-4484-B2AB-3A80FA3DFCD0Q56890615-B11A40F6-3738-49A9-B4A0-EAD1792C0EE3Q56917730-5D3CD31D-111C-4768-9AEA-D1A8391EB993Q58775051-D818B219-A081-43CA-8A39-89D5F181CC88
P2860
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@en
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@nl
type
label
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@en
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@nl
prefLabel
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@en
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@nl
P2093
P50
P356
P1476
Modelling antiviral treatment ...... drugs in Victoria, Australia.
@en
P2093
Margaret E Hellard
Mark A Stoové
Natasha K Martin
Rebecca Jenkinson
P304
P356
10.5694/MJA11.10981
P407
P577
2012-06-01T00:00:00Z